RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FDA guides on how AA can be converted to full approval.Reportedly the cost for a course of intravenous checkpoint inhibitor therapy is around $US150,000 to $250,000 while the rate of effectiveness is between 10 - 20 %.
With ONCY's pelareoep continuing to prove synergistic effectiveness in combination with PD-(L)1 immune checkpoint inhibitors, the increased degree of efficacy would result in an increased number of patients who could be placed on PD-(L)1 immune checkpoint inhibitor therapy, and this increase in patient numbers could result in an overall decrease of checkpoint inhibitor cost, thus making it more accessible to more patients.
The plausible ability to reduce the cost of PD-(L)1 immune checkpoint inhibitors when combined with pelareorep, would seem to make the acquisition of ONCY an attractive proposition for Big Pharma companies with ICIs.
https://www.globenewswire.com/news-release/2023/02/13/2607142/0/en/Checkpoint-Inhibitors-Global-Market-Report-2023.html